Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to -$618,000.

  • Aytu Biopharma's Free Cash Flow rose 53.39% to -$618,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year increase of 48.55%. This contributed to the annual value of -$2.2 million for FY2025, which is 26.09% down from last year.
  • Latest data reveals that Aytu Biopharma reported Free Cash Flow of -$618,000 as of Q3 2025, which was down 122.18% from $2.8 million recorded in Q2 2025.
  • Aytu Biopharma's Free Cash Flow's 5-year high stood at $19.7 million during Q1 2021, with a 5-year trough of -$9.1 million in Q3 2022.
  • For the 3-year period, Aytu Biopharma's Free Cash Flow averaged around $179,182, with its median value being -$254,000 (2024).
  • Per our database at Business Quant, Aytu Biopharma's Free Cash Flow soared by 2,247.41% in 2024 and then tumbled by 2,468.50% in 2025.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Free Cash Flow stood at -$8.8 million in 2021, then soared by 72.18% to -$2.5 million in 2022, then surged by 94.49% to -$135,000 in 2023, then skyrocketed by 2,247.41% to $2.9 million in 2024, then spiked by 53.39% to -$618,000 in 2025.
  • Its Free Cash Flow was -$618,000 in Q3 2025, compared to $2.8 million in Q2 2025 and -$6.5 million in Q1 2025.